LEADS BIOLABS-B Surges Over 4% as Phase II Study for Biliary Tract Cancer Advances

Stock News09:44

LEADS BIOLABS-B (09887) rose more than 4%, with the stock up 4.39% to HK$93.9 at the time of writing. The trading volume was HK$13.3778 million. On April 8, LEADS BIOLABS announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. Based on favorable safety and encouraging efficacy data, the project has smoothly progressed into the expansion phase, with the first patient already enrolled. Data indicates that Vilisin® in combination with chemotherapy demonstrated a good overall safety profile and tolerability, with no new safety signals identified. Preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage. Owing to the positive safety and efficacy results, the project has successfully entered the expansion stage and is accelerating its development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment